[Urology: what's new in 2022]
Nelson Peixoto1, Julien Renard1, Olivier Windisch1
1Service d'urologie, Département de chirurgie, Hôpitaux universitaires de Genève, 1211 Genève 14.
Abstract:
Over the last year, urologic progress remains driven by evolutions in oncological and functionnal urology. Prostate cancer imaging modalities are improving, as well as treatment options for advanced stages. Kidney and bladder cancer are benefiting from new treatment modalities including immunotherapy, whose role in the peri-operative setting is still unclear. Surveillance startegies for testicular cancer has been greatly simplified, for the benefit of the patients. In functional urology, a new therapeutic class in now available for the treatment of overactive bladder. Mutliples alternatives to transurethral resection are emerging in the surgical treatment of benign prostatic hypertrophy, whose expected benefits will need to be validated by long-term studies.
Insights
Recent urologic advancements focus on improved prostate cancer treatments and simplified testicular cancer surveillance. New therapies for overactive bladder and benign prostatic hypertrophy are emerging, while immunotherapy
Area of Science:
- Urology
- Oncological Urology
- Functional Urology
Context:
- Urologic progress is advancing rapidly, particularly in oncological and functional urology.
- Significant developments have occurred in prostate cancer imaging and treatment for advanced stages.
- New treatment modalities, including immunotherapy, are being explored for kidney and bladder cancers, with ongoing research into their peri-operative applications.
Purpose:
- To review recent advancements in oncological and functional urology over the past year.
- To highlight key developments in prostate, kidney, bladder, and testicular cancer management.
- To discuss emerging treatments for overactive bladder and benign prostatic hypertrophy.
Summary:
- Prostate cancer care is improving with enhanced imaging and advanced-stage treatments.
- Immunotherapy shows promise for kidney and bladder cancers, though its peri-operative use requires further study.
- Testicular cancer surveillance is simplified, and new treatments for overactive bladder and benign prostatic hypertrophy are emerging.
Impact:
- These advancements offer improved patient outcomes and simplified management strategies in urologic care.
- The introduction of new therapeutic classes and surgical alternatives promises to enhance treatment efficacy.
- Further long-term studies are needed to validate the benefits of emerging treatments for benign prostatic hypertrophy.
Related Concept Videos
Imaging Studies V: Intravenous Urography and Retrograde Pyelography
Urinary Tract Calculi VI: Surgical Management
Urodynamic Studies: Uroflowmetry
Anatomy of the Genitourinary System II: Bladder and Urethra
Urinary Tract Calculi III: Medical Management
Urologic Endoscopic Procedure: Cystoscopic Examination


